Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009452 | 1.00 | PDK1 (0.38) | PDK1PDK2PDK3PDK4EPHX1 | |
| SCHEMBL6009955 | 0.98 | PDK1 (0.40) | PDK1PDK2PDK3PDK4EPHX1 | |
| SCHEMBL6008745 | 0.98 | PDK1 (0.40) | PDK1PDK2PDK3PDK4EPHX1 | |
| SCHEMBL6009989 | 0.76 | HDAC6 (0.33) | EPHX1 | |
| SCHEMBL5505514 | 0.76 | HDAC6 (0.33) | EPHX1 | |
| SCHEMBL6009434 | 0.75 | HDAC6 (0.35) | PDK1PDK2PDK3PDK4EPHX1 | |
| SCHEMBL6009453 | 0.75 | HDAC6 (0.35) | PDK1PDK2PDK3PDK4EPHX1 | |
| SCHEMBL5501481 | 0.71 | PDK1 (0.34) | PDK1PDK2PDK3PDK4EPHX1 | |
| SCHEMBL6009968 | 0.71 | PDK1 (0.38) | PDK1PDK2PDK3PDK4EPHX1 | |
| SCHEMBL6009916 | 0.71 | PDK1 (0.38) | PDK1PDK2PDK3PDK4EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | PDK1 4844/4885PDK2 4374/4885PDK3 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.